Biotechnology company Bharat Biotech has introduced world's first clinically proven typhoid conjugate vaccine, Typbar-TCV, to protect infants aged six months and more and adults from typhoid fever caused by Salmonella typhi.
Commercial production of Typbar-TCV in pre-filled syringes has commenced in the company's Genome Valley vaccine production facility, which has a capacity to produce 10 million doses every year, expandable to 50 million doses per year.
Bharat Biotech chairman and managing director Dr Krishna Ella said the company's Typbar-TCV induces 'T' cell dependent response with much higher antibody levels providing a very high rate of immunity.
"We hope this vaccine will reach millions of people and help reduce the burden of this devastating disease in infants and children." Dr. Ella added.
The fourth generation vaccine against typhoid disease, Typbar-TCV is available in markets such as South East Asia, South America, Africa, Central Asia, and South Asia.
During development, the vaccine was assessed in around 1200 healthy subjects at nine clinical sites in the pivotal Phase III study, in which it proved to be superior to the Vi polysaccharide typhoid vaccines.
